Fluoxiuridine (FUDR) chronoinfusion through a subcutaneous pump seems to give a 24% objective response rate with mild side effects. From April 1992 to December 1993 we included 18 patients with metastatic renal cell cancer and good performance status (ECOG 0-2) in a phase II study. In our experience we observed a 16% objective response rate without any major side effect. Based on these results we suggest a phase III prospective randomized study.
ProutG.R.Jr., GarnickM.B.: The kidney and ureter. Chap. XXVI-2. In: HollandJ., FreiE.III, Cancer Medicine; Lea and Febiger, Philadelphia, III ed. 1990.
2.
RosembergS.A., LotzeM.T., MuleJ. J.: New approaches to the immunotherapy of cancer using Interleukin-2. Ann. Int. Med., 108: 853–864, 1988.
3.
RosembergS.A., LotzeM.T., YangJ.C., AebersoldP.M., LinehanW.M., SeippC.A., WhiteC. E.: Combination therapy with Interleukin-2 and alpha-Interferon for treatment of patients with advanced cancer. J. Clin. Oncol., 7 (12): 1863–1874, 1989.
4.
HrusheskyW.J.M., RoemelingV.R., FraleyE.E., RabatinJ.T.: Circadian based chrono-chemiotherapy controls progressive metastatic renal cell carcinoma. Seminars in Surgical Oncology, 4: 110–115, 1988.
5.
QuesadaJ.R., SwansonD. A.: Renal carcinoma: antitumour effects of leukocyte interferon. Cancer Res., 43: 940, 1983.
6.
NeidhartJ.A., GagenM.: Unexplained spontaneous regression and alpha-Interferon as treatment for metastatic renal carcinoma. Cancer Res., 44: 41, 40, 1984.
7.
BelldegrunA., RosembergS.A.: Adoptive immunotherapy of urologic tumours. Cancer Treat. Res., 46: 213–33, 1989.
8.
SchillerJ.H., HankJ., StorerB., BorchertA.A., Hu-sebyMoore K., AlbertiniM., BechhoferR., WesleyO., BrownR.R., MrowcaBastan A., SondelP.: A direct comparison of immunological and clinical effects of Interleukin 2 with and without Interfeon-a in humans. Cancer Res., 53: 1286–1292, 1993.
9.
HirshM., LiptonA., HarveyH.: Phase I study of Interleukin-2 and Interferon alpha-2a as outpatient therapy for patients with advanced malignancy. J. Clin. Oncol., 8: 1657–1659, 1990.
10.
DimopoulosM.A., DexeusF.H., JonesE., AmatoR.J., SellaA., LogothetisC.J.: Evidence of additive antitumour activity and toxicity for the combination of FUDR and interferon alpha-2b (IFN-Alpha Intron) in patients with metastic renal cell carcinoma (RCC). Proc. Am. Assoc. Cancer Res., 32: 186, 1991.
11.
EsgroJ.J., KillionJ.J., FidlerI. J.: Modulation of the antiproliferative effects of Fuoxiuridine by Interferon beta against human colon carcinoma cells. Proc. Ann. Meet. Am. Assoc. Cancer Res., 31: 2525, 1990.
12.
ContiG., CappoliS., GianneoE., ComeriG.C., Fri-gerioL., MarchianoA., DamascelliB.: Continuous chemotherapy with Fluoxiuridine (FUDR) by an implantable pump in renal cell carcinoma (RCC): 3-years experience. European Urol., 18 (suppl. 1): 147, 1990.
13.
DamascelliB., MarchianoA., SpreaficoC., LutmanR., SalvettiM., BonalumiM.G., MauriM., GarbagnatiF., Del NeroA., ComeriG., ContiG., CoppoliS., Benet-tiG., TralongoP., BelussiD.: Circadian continuous chemotherapy of renal cell carcinoma with an implantable programmable infusion pump. Cancer, 66 (2): 237–41, 1990.
14.
Dal BiancoM., GuatelliS., Prayer-GalettiT., Avo-garoF., BaruscoG.: FUDR in cronoinfusione e Interferone nel trattamento delle metastasi da carcinoma renale parenchimale. Urol., 59 (6), 1992.
